id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2004-P-0338-0006,FDA,FDA-2004-P-0338,FDA-CDER to Valeant Pharmaceuticals International - Response,Other,PDN-Petition Denial,2009-08-07T04:00:00Z,2009,8,2009-08-07T04:00:00Z,,2009-08-07T13:26:53Z,,0,0,0900006480524706
FDA-2004-P-0338-0005,FDA,FDA-2004-P-0338,Ted Sherwood,Other,MM-Memorandum of Meeting,2007-11-20T05:00:00Z,2007,11,,,2008-04-12T00:49:25Z,,0,0,0900006480473328
FDA-2004-P-0338-0003,FDA,FDA-2004-P-0338,HFD-5 to Valeant Pharmaceuticals International,Other,LET-Letter,2005-07-01T04:00:00Z,2005,7,,,2008-04-12T00:49:25Z,,0,0,0900006480473300
FDA-2004-P-0338-0004,FDA,FDA-2004-P-0338,HFD-5 to Valeant Pharmaceuticals International,Other,LET-Letter,2005-07-01T04:00:00Z,2005,7,,,2008-04-12T00:49:25Z,,0,0,0900006480473301
FDA-2004-P-0338-0001,FDA,FDA-2004-P-0338,HFA-305 to Valeant Pharmaceuticals International,Other,ACK-Acknowledgement Letter,2004-12-22T05:00:00Z,2004,12,,,2008-04-12T00:49:25Z,,0,0,09000064804732f6
FDA-2004-P-0338-0002,FDA,FDA-2004-P-0338,HFA-305 to Valeant Pharmaceuticals International,Other,ACK-Acknowledgement Letter,2004-12-22T05:00:00Z,2004,12,,,2008-04-12T00:49:25Z,,0,0,09000064804732ff